Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia

Endocrine Practice

Volumn 14, Issue 6, 2008, Pages 672-677

  Devin, Jessica K ^a   Lakhani, Vipul T ^b   Byrd III, Benjamin F ^b   Blevins Jr , Lewis S ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PERGOLIDE; ERGOLINE DERIVATIVE;

ADULT; AGED; AORTA VALVE DISEASE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HUMAN; HYPERPROLACTINEMIA; MALE; MITRAL VALVE REGURGITATION; RETROSPECTIVE STUDY; TREATMENT DURATION; VALVULAR HEART DISEASE; CHEMICALLY INDUCED DISORDER; MIDDLE AGED;

ADULT; COHORT STUDIES; ECHOCARDIOGRAPHY; ERGOLINES; FEMALE; HEART VALVE DISEASES; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED;

EID: 64749099041     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.6.672     Document Type: Article

References (19)

1. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356:39-46.
2. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356:29-38.
3. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology. 2006;67:1225-1229.
4. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord. 2004;19:656-662.
5. Junghanns S, Fuhrmann JT, Simonis G, et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord. 2007;22:234-238.
6. Kenangil G, Ozekmekçi S, Koldas L, Sahin T, Erginöz E. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. Clin Neurol Neurosurg. 2007;109:350-353.
7. Martin M, Iglesias-Cubero G, Diaz Molina B, Moris De la Tassa C. Mitral heart disease due to cabergoline. Int J Cardiol. 2007;114:e7-e8.
8. Peralta C, Wolf E, Alber H, et al. Valvular heart disease in Parkinson's disease vs. controls: an echocardiographic study. Mov Disord. 2006;21:1109-1113.
9. Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007;356:6-9.
10. Martin WR. Dopamine agonists and the risk of valvular heart disease. Nat Clin Pract Neurol. 2007;3:426-427.
11. Kvernmo T, Härtter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28:1065-1078.
12. Zoghbi WA, Enriquez-Sarano M, Foster E, et al (American Society of Echocardiography). Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16:777-802.
13. Reid CL, Anton-Culver H, Yunis C, Gardin JM. Prevalence and clinical correlates of isolated mitral, isolated aortic regurgitation, and both in adults aged 21 to 35 years (from the CARDIA study). Am J Cardiol. 2007;99:830-834.
14. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) [published correction appears in Am J Cardiol. 1999;84:1143]. Am J Cardiol. 1999;83:897-902.
15. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation. 2000;101:2071-2077.
16. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT (Sustained-Release Dexfenfluramine Study Group). An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med. 1998;339:725-732.
17. Delgrange E. Cabergoline and mitral regurgitation. N Engl J Med. 2006;354:420.
18. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA. 2000;283:1703-1709.
19. Burger AJ, Sherman HB, Charlamb MJ, et al. Low prevalence of valvular heart disease in 226 phenterminefenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol. 1999;34:1153-1158.